247 / 1578
/
ESTRO SBRT COURSE 2017 - Matthias Guckenberger
21
Agent
Patients
Studies
Primary Tumor
SRT Location
Antibodies
Bevacizumab
202
11
Glioma, NSCLC, CRC
Brain
Cetuximab
251
6
SCCHNC
Head-and-neck
Trastuzumab
7
1
Mamma
Brain
Ipilimumab
121
8
Melanoma, Adenocarcinoma
Lung
Brain, Liver
Nivolumab
27
2
Melanoma
Brain
TKIs
Sorafenib
142
3
RCC, HCC, CRC
Brain, Spine, Abdomen
Sunitinib
15
2
RCC, Lung, Breast, Melanoma,
Brain, Abdomen
Gefitinib
47
3
NSCLC, Glioma
Brain, Lung
Erlotinib
24
1
NSCLC
Abdomen, Lung, Bone
Crizitonib
39
2
NSCLC
Brain, Lung, Abdomen, Bone
Vemurafenib
75
6
Melanoma
Brain, Spine
Dabrafenib
56
4
Melanoma
Brain
Trametinib
6
1
Melanoma
Brain
Evidence of combining SBRT & targeted
drugs
•
Very little data available: 1042 patients in 50 studies
07.09.17
/
Brain metastases
Low tech
Whole brain irradiation
High tech
Radiosurgery
Andrews Lancet 2004
•
High tech in palliative setting in good prognosis patients
Ø
Aim: prolongation of OS
ESTRO SBRT COURSE 2017 - Matthias Guckenberger
22
07.09.17